CONMED Corp reported a solid Q4 2025 with revenue surpassing $1.37 billion annually, driven by growth in orthopedic and general surgery devices. The company strategically manages its capital structure through limited term loan borrowings, an ample revolving credit facility, and a $150 million share repurchase program while suspending dividends to preserve liquidity amid a sizable convertible note maturity in 2027. Continued R&D investment supports innovation across powered instruments, imaging systems, and electrosurgical generators, sustaining competitiveness within a diversified global footprint where approximately 44% of sales derive from outside the U.S. Intellectual property challenges and supply chain risks remain material headwinds but are addressed through operational optimization and broad risk management.